Upon treatment of tumor models with an anti-TNFRSF4 monoclonal antibody, IL-10 production by tumor-infiltrating Treg cells is reduced, allowing the maturation of dendritic cells (Burocchi et al., 2011; Zhang et al., 2018), creating a permissive immune state that allows for the maturation of dendritic accumulation of myeloid cells and development of innate and adaptive immunity (Piconese et al., 2008; Bulliard et al., 2014), opening an additional avenue for cancer therapy. Here, TNFRSF4 is linked to cancer.